GAMA
RIGL icon

Graticule Asia Macro Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Graticule Asia Macro Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,800
Closed -$653K – 136
2016
Q3 		$653K Buy
+17,800
New +$510K 0.05% 89

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Graticule Asia Macro Advisors's RIGL Position: Q4 2016 in Review

Graticule Asia Macro Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q4 2016, closing a stake of 17,800 shares — an estimated $653K sold.

Graticule Asia Macro Advisors first reported a position in RIGL in Q3 2016 and held it in 1 quarter. The position peaked at $653K in Q3 2016. 107 funds tracked by Wall St. Rank hold RIGL as of Q4 2016.

  • Graticule Asia Macro Advisors reported no remaining Rigel Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 17,800 Rigel Pharmaceuticals shares in Q4 2016, an estimated $653K.
  • Graticule Asia Macro Advisors first reported a position in Rigel Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Rigel Pharmaceuticals position peaked at $653K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2016.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.